Optellum and GE Healthcare have signed a letter of intent (LoI) to work together to advance the diagnosis of lung cancer with artificial intelligence (AI).

The collaboration aims to help healthcare providers determine the malignancy of lung nodules that are difficult to diagnose, enabling them to expedite subsequent treatment.

Optellum stated that its AI-powered software, Virtual Nodule Clinic, helps to identify and score the malignancy probability of a lung nodule. It is capable of enhancing the specificity and sensitivity of indeterminate nodule malignancy assessments.

This will help reduce the need to perform biopsies or surgical resection procedures to determine malignant modules, thereby accelerating diagnostic processes.

The Virtual Nodule Clinic is claimed to be the only AI-assisted diagnosis software approved by the US Food and Drug Administration (FDA) for early-stage lung cancer.

As part of the collaboration, GE Healthcare plans to work with Optellum to integrate AI solutions powered by GE Healthcare’s Edison platform into the Virtual Nodule Clinic.

The company will also work with Optellum’s sales team to distribute the platform.

Additionally, Optellum and GE Healthcare are planning to bring Optellum’s Lung Cancer Prediction AI results into the existing workflow of many GE Healthcare technological pathways that currently include picture archiving and communication system (PACS) and computed tomography (CT).

GE Healthcare oncology solutions general manager Ben Newton said: “The precise diagnosis of lung cancer can greatly improve patient prognosis.

“The integration of imaging and medical device data from the Edison Platform with AI-enabled solutions like the one offered by the Optellum Virtual Nodule Clinic has the potential to streamline clinician workflows and advance our goal of making precision healthcare, taking the right action at the right time for every patient, at scale, as widely accessible as possible.”